Trial Profile
Feasibility, safety, efficacy and immunogenicity of MUC1 CEA ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine in patients with stage IV renal cell carcinoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jul 2014
Price :
$35
*
At a glance
- Drugs MUC1 CEA ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 29 Jul 2014 New trial record